I don’t think so. They cleaned up the website in January to imply they are strictly focused on Onc. This was a very quick pivot after everyone was under the impression that we were focused on MASH. The AMEREX data was a mess and they were sorting through the master file and they found out that we had an apparent situation where patients are actually living cancer free many years after last, taking LL. So they had to go find these patients and they did and the posters in Munich and Barcelona demonstrate what they found.
So because the website and what they’ve telegraphed to to the world say Onc, does that mean that these other indications and disease states are not a focus? Highly doubtful. Jay told us last month that Alzheimer’s has the greenlight and we also know that stroke and ischemic Neuro events are on the radar as well.
I believe they are focused on dialogue involving partnerships for Onc as a starting point. I also think this is the right approach. It’s our fastest way to approval.